At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 16, 2026 at 08:39 ET
GeneDx appointed Mark Gardner as President, effective June 15, 2026, to oversee lab and commercial operations. Gardner, a former Quest Diagnostics executive, received a compensation package including a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units. This is a routine executive hire with no financial data or guidance provided.
- Mark Gardner appointed President effective June 15, 2026, reporting to CEO Katherine Stueland
- Gardner previously served as SVP of Molecular Genomics and Oncology at Quest Diagnostics (Sept 2022, June 2026)
- Employment agreement: $530,000 annual base salary, 65% target bonus, $2,000,000 in RSUs vesting over 4 years
- Bryan Dechairo transitions to lead product, technology and innovation initiatives
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access